Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/350894
Genetic Engineering & Biotechnology News | GENengnews.com | AUGUST 2014 | 41 PEOPLE Scioderm named Ronald Nardi, Ph.D., as CSO...Caris Life Sciences appointed Anna Baker, Ph.D., George Demetri, M.D., Clay Marsh, M.D., Frank Mc- Cormick, Ph.D., William N. Narwin, M.D., John Quackenbush, Ph.D., Bruce Quinn, M.D., Ph.D., Leonard Sender, M.D., Lee Schwartzberg, M.D., Jeffrey Vacirca, M.D., Nick Vogelzang, M.D., to its scientifc board...Neurotrope add- ed Sam Kongsamut, Ph.D., as executive director, pharmacology...C4X Discovery elected Piers Morgan as CEO...Spark Therapeutics appointed Lars Ekman, Vin Milano, and Anand Mehra to its board of directors. Avillion named Ulf Wiinberg as chair- man of its board of directors...Retrogenix added Matthew Britz as North American business development director...Dyadic International appointed Michael Tar- nok to its board of directors, audit, and compensation committees...Peter Hirth, Ph.D., joined Nuevolution as a corporate advisor...PuriCore named Charles Spicer as nonexecutive chairman of its board of directors...Prosensa Holding hired Wil- lem W. van Weperen as chief commer- cial offcer and named Annalisa Jenkins, M.D., to its supervisory board...Sally A. Berry, M.D., Ph.D., is now CMO and Norma Capetti is vp of regulatory affairs at Tris Pharma. Bristol-Myers Squibb elected Giovanni Caforio, M.D., as COO and to its board of directors…Cepheid hired Peter Farrell as evp of international commercial op- erations…Dendreon appointed Douglas G. Watson as chairman of the company's board of directors…Amgen added David W. Meline as evp and CFO…Quanterix appointed Kevin Hrusovsky as executive chairman of its board of directors...Ted W. Love, M.D., is now CEO at Global Blood Therapeutics. StemCells promoted Stephen Huhn, M.D., to vp of CNS clinical research and added CMO, Joel Naor, M.D., as vp of clinical development, ophthalmology, Naymisha Patel as vp of quality systems, and Mohammad A. El-Kalay, Ph.D., as vp of process development. Amorfx Life Sciences named William Wyman as chairman of its board of di- rectors...Retrogenix appointed Matthew Britz as North American business devel- opment director. Ariad Pharmaceuticals appointed Timothy Maines (left) as vp, quality, Yan Moore, M.D., (middle) as vp, medical afairs, and Piet A.M. Vervaet, M.D., (right) as vp, drug safety and pharmacovigilance of its global management team. Before joining Ariad, Maines served as vp of quality at Omthera Pharmaceuticals. Dr. Moore was formerly associate vp, global medical afairs at Sanof. Dr. Vervaet was vp, drug safety and pharmacovigilance at Onyx Pharmaceuticals. Synergy Phar- maceuticals named Paul Eng, Ph.D., as svp, drug development. Formerly, Dr. Eng was director of gastroenterol- ogy clinical development at Forest Laboratories. Prior to joining Forest, he served in positions at American Home Products and Life Medical Sciences. Kolltan Pharmaceuticals promoted Jane Henderson (left) to CFO and CBO and added Keith J. C. Darragh (right) as vp of fnance and adminis- tration. Prior to Kolltan, Henderson served as vp, business development at ISTA Pharmaceuticals and evp, CFO, and CBO of Panacos Pharmaceuticals. Darragh joins Kolltan from Vision- Sciences where he served as principal fnancial and accounting ofcer and vp of fnance. Previously, he was U.S. assistant controller at Eisai. Robert G. Pietrusko joined Voyager Therapeutics as svp of regulatory af- fairs. Previously, he was vp, global reg- ulatory afairs and quality and execu- tive ofcer at ViroPharma. Before that, Editas Medicine hired Katrine Bosley as CEO. Most recently, she was CEO of Avila Therapeutics. Prior to that, Bosley was vp, business development at Adnexus Therapeutics. Earlier, she Dr. Pietrusko was svp of worldwide regulatory af- fairs at Millen- nium Pharma- ceuticals. held positions at Biogen Idec in business development, commercial operations, and portfolio strategy. Send your People Announcements to people@GENengnews.com Advertiser Index 3D Printing and Additive Manufacturing . . . . . . . . . . 20 Advanced Analytical . . . . . . . . . . . . . . . . 37 Afymetrix . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Applikon Biotechnology . . . . . . . . . . . . 27 Bio-Rad . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Biosearch Technologies . . . . . . . . . . . . . 15 Clinical OMICs . . . . . . . . . . . . . . . . . . . . . . 41 DxTerity Diagnostics . . . . . . . . . . . . . . . 16 EMD Millipore . . . . . . . . . . . . . . . . .22,23,43 Enzymatics . . . . . . . . . . . . . . . . . . . . . . . . . 3 Eppendorf . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Eppendorf/Dasgip . . . . . . . . . . . . . . . . . 25 Finesse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 GEN/Renew Now . . . . . . . . . . . . . . . . . . . . 5 IBC USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Illumina . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Infors HT . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 InvivoGen . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Life Technologies— A Thermo Fisher Scientifc Brand . . . . . . 13 Merck Millipore . . . . . . . . . . . . . . .22,23,43 OriGene . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 PerkinElmer . . . . . . . . . . . . . . . . . . . . . . . . 29 Promega . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Roche Diagnostics . . . . . . . . . . . Cover Tip Sartorius Stedim Biotech . . . . . . . . . . . . .4 Seahorse Bioscience . . . . . . . . . . . . . . . 17 Swift Biosciences . . . . . . . . . . . . . . . . . . . 35 TriLink BioTechnologies . . . . . . . . . . . . . 28 Waters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Reprints Karen Ballen 914-740-2194 reprints@GENengnews.com GEN offers reprints of individual articles — in printed or electronic form — to increase awareness of your product or company. Order today! Subscribe Clinical OMICs will extend GEN's comprehensive coverage to the clinic by focusing on the application of revolutionary molecular technolo- gies in medical practice. To p i c s t o b e c ove re d i n c l u d e p e r sonalized and precision medicine, next-gen sequencing, bioinformatics, reim- b u r s e m e n t , a n d b i o e t h i c s . To see past issues, recent news, and sub- scribe, go to: www.clinicalomics.com TO GEN'S NEW e-PUB Innovative Practices, Actionable Results